A study to investigate whether LJM716 in combination with cetuximab is safe and has beneficial effects in patients with advanced head and neck cancer who progressed on prior therapy

Mise à jour : Il y a 5 ans
Référence : EUCTR2013-005540-28

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Phase Ib: To determine RP2D and estimate MTD of LJM716 in combination with cetuximab in patients with RM HNSCC Phase II: To access the anti-tumor activity of LJM716-cetuximab combination in cetuximab naïve (Group A) and cetuximab pretreated (Group B) patients with RM HNSCC


Critère d'inclusion

  • Head and neck squamous cell carcinoma

Liens